8-K/A: Scholar Rock Updates on Apitegromab, Secures $550M Debt

Scholar Rock reported Q4 and full-year 2025 financial results, provided updates on apitegromab's regulatory path, and secured a new $550 million debt facility.

Summary

• Scholar Rock reported a net loss of $91.0 million for the fourth quarter ended December 31, 2025, compared to $66.5 million for the same period in 2024.
• The full-year 2025 net loss was $377.9 million, an increase from $246.3 million for the full year 2024.
• Apitegromab's Biologics License Application (BLA) resubmission and U.S. launch are anticipated in 2026, contingent on a successful FDA reinspection of the Catalent Indiana facility.
• The European Medicines Agency (EMA) decision on the apitegromab Marketing Authorisation Application (MAA) is expected in mid-2026, with a European launch planned for the second half of 2026, starting with Germany.
• The company secured a new debt facility providing up to $550 million in non-dilutive capital to support the commercialization of apitegromab and strategic advancement of key pipeline programs.
• Cash, cash equivalents, and marketable securities totaled $367.6 million as of December 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as moderately positive. While financial losses widened due to increased R&D and G&A, the significant non-dilutive financing and positive regulatory progress for apitegromab's BLA resubmission and European MAA provide a strong foundation for anticipated commercialization in 2026.

Positives

• FDA completed a constructive meeting with Catalent Indiana, LLC, discussing remediation progress with no additional corrective actions requested by the FDA.
• Apitegromab BLA resubmission and U.S. launch are still anticipated in 2026, following FDA approval.
• Apitegromab Marketing Authorisation Application (MAA) review is ongoing with the EMA, with a decision expected in mid-2026 and European launch in H2 2026.
• Secured a new debt facility providing up to $550 million in non-dilutive capital, enhancing financial flexibility for commercialization and pipeline advancement.
• Progress on a second U.S.-based fill-finish facility for apitegromab to strengthen supply continuity, with a supplemental BLA expected later in 2026.
• Advancement of pipeline programs, including the ongoing Phase 2 OPAL study for apitegromab in infants/toddlers with SMA, development of subcutaneous apitegromab, and initiation of Phase 2 FORGE trial for FSHD in mid-2026.
• SRK-439 Phase 1 healthy volunteer study is underway, with topline data expected in H2 2026.

Negatives

• Net loss for Q4 2025 increased to $91.0 million from $66.5 million in Q4 2024.
• Net loss per common share for Q4 2025 increased to $0.76 from $0.61 in Q4 2024.
• Full-year 2025 net loss significantly increased to $377.9 million from $246.3 million in 2024.
• Full-year 2025 net loss per common share increased to $3.29 from $2.47 in 2024.
• General and administrative expense for Q4 2025 increased to $45.0 million from $19.0 million in Q4 2024.
• Full-year 2025 general and administrative expense increased to $176.2 million from $67.5 million in 2024.
• Research and development expense for full-year 2025 increased to $208.4 million from $184.5 million in 2024.

Risks

• Preclinical and clinical data, including the results from the Phase 3 SAPPHIRE trial, may not be sufficient to support regulatory approval.
• Preclinical and clinical data may not be predictive of, inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidates.
• Uncertainty regarding whether the FDA will accept the remediations to the Novo Nordisk Bloomington Indiana fill-finish facility in response to the FDA Observations.
• Uncertainty regarding Scholar Rock's ability to resubmit its BLA in a timely manner and whether the updated BLA will be sufficient to support regulatory approval.
• Scholar Rock's ability to manage expenses or provide the financial support, resources, and expertise necessary to identify and develop product candidates on the expected timeline.
• Information provided or decisions made by regulatory authorities could impact development and approval timelines.
• Competition from third parties that are developing products for similar uses.
• Scholar Rock's ability to obtain, maintain, and protect its intellectual property.
• Scholar Rock's dependence on third parties for development and manufacture of product candidates, including to supply any clinical trials.

Future Outlook

Scholar Rock anticipates apitegromab's BLA resubmission and U.S. launch in 2026, pending successful FDA reinspection of the Catalent Indiana facility. An EMA decision on the MAA is expected by mid-2026, with a European launch in H2 2026. The company plans to initiate the Phase 2 FORGE trial for FSHD in mid-2026 and expects topline data for the SRK-439 Phase 1 study in H2 2026. A supplemental BLA for a second fill-finish facility is also expected later in 2026.

Management Comments

• "Our highest priority is to serve children and adults living with SMA by bringing apitegromab through the regulatory review process as quickly as possible."
• "We are encouraged by the FDAs continued engagement and shared sense of urgency as Novo Nordisk works expeditiously to remediate its Catalent Indiana facility."
• "We are ready to resubmit our apitegromab BLA following successful reinspection of the site by the FDA."
• "As we prepare to usher in the next phase of innovation for patients with SMA, we continue to strengthen our financial position while aggressively advancing our pipeline and expect 2026 to be a transformative year for Scholar Rock."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry, particularly in rare neuromuscular diseases like SMA and FSHD, is highly competitive and capital-intensive. Scholar Rock's focus on myostatin biology positions it in a niche with significant unmet medical needs. The regulatory hurdles, as seen with the Catalent Indiana facility, highlight the complexities of drug manufacturing and approval processes, which are common challenges across the industry. The securing of a substantial non-dilutive debt facility is a strategic move to fund commercialization and pipeline development without immediate equity dilution, a common financing approach for late-stage biotech companies nearing commercialization.

Stakeholder Impact

• Shareholders: Potential for future value creation if apitegromab is approved and successfully commercialized, supported by the new non-dilutive debt facility. However, increased net losses and expenses indicate continued cash burn in the near term.
• Patients (SMA/FSHD): Continued progress towards bringing apitegromab to market in the U.S. and Europe, offering a potential new treatment option. Advancement of other pipeline programs also offers future hope.
• Employees: Continued focus on commercialization and pipeline development suggests stability and growth opportunities.
• Creditors (Blue Owl Capital): Provided significant financing, indicating confidence in Scholar Rock's future prospects and apitegromab's potential.
• Regulatory Authorities (FDA, EMA): Ongoing engagement and review processes are critical for product approval and market access.

Next Steps

• Resubmit apitegromab BLA following successful FDA reinspection of Catalent Indiana.
• Continue U.S. commercial team preparations for apitegromab launch.
• Await EMA decision on apitegromab MAA in mid-2026.
• Plan for apitegromab launch in Europe in H2 2026, starting with Germany.
• Continue technology transfer and manufacturing runs at the second fill-finish facility.
• Submit a supplemental BLA (sBLA) for the second fill-finish facility later in 2026.
• Continue enrollment and patient dosing in the Phase 2 OPAL study for SMA.
• Advance development activities for subcutaneous apitegromab, including planned FDA and EMA regulatory engagements.
• Initiate Phase 2 FORGE trial for FSHD in mid-2026.
• Await topline data from the SRK-439 Phase 1 healthy volunteer study in H2 2026.
• Draw down an additional $100 million from the new debt facility in Q1 2026.
• Host a conference call and webcast on March 3, 2026, at 8:00 a.m. ET.

Key Dates

Recommendation

While Scholar Rock reported widening losses for Q4 and full-year 2025, the company made significant strides in de-risking its lead asset, apitegromab. The constructive FDA meeting regarding the Catalent Indiana facility and the clear path to BLA resubmission, coupled with the substantial non-dilutive debt financing, provide a strong foundation for anticipated commercialization in 2026. However, the increased cash burn and the remaining regulatory hurdles (FDA reinspection, EMA decision) warrant a 'hold' recommendation until further clarity on approval and initial commercial traction is established. The long-term potential remains, but near-term execution risks persist.

Keywords

Scholar Rock, SRRK, apitegromab, spinal muscular atrophy, SMA, myostatin inhibitor, biopharmaceutical, FDA approval, EMA review, debt facility, FSHD, SRK-439, clinical trials, rare neuromuscular diseases, Catalent Indiana